Carsten spoke about the approval of CTA by the Dutch regulatory authority for a P-I study evaluating its TCR therapy for the treatment of solid tumorsCarsten also emphasized how NT-125 will be different from other TCR therapiesThe interview shows the advancement of Neogene’s pipeline developing transformative TCR therapies targeting neoantigens in solid cancers…
